Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completion of a qualifying Ra Pharmaceuticals sponsored zilucoplan (RA101495) PNH study~* Evidence of ongoing clinical benefit in the opinion of the Investigator~Exclusion criteria:~* History of meningococcal disease~* Current systemic infection or suspicion of active bacterial infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zilucoplan (RA101495) (Type: EXPERIMENTAL): Subjects will continue to receive the final maintenance dose they were receiving in the qualifying study

Based on this trial design, predict the completion outcome and termination type (if applicable).